vs
Side-by-side financial comparison of Dayforce (DAY) and HAEMONETICS CORP (HAE). Click either name above to swap in a different company.
Dayforce is the larger business by last-quarter revenue ($481.6M vs $339.0M, roughly 1.4× HAEMONETICS CORP). HAEMONETICS CORP runs the higher net margin — 13.2% vs -40.9%, a 54.1% gap on every dollar of revenue. On growth, Dayforce posted the faster year-over-year revenue change (9.5% vs -2.7%). Over the past eight quarters, Dayforce's revenue compounded faster (9.8% CAGR vs 0.4%).
Dayforce, Inc., formerly Ceridian, is an American human resources software and services company.
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
DAY vs HAE — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $481.6M | $339.0M |
| Net Profit | $-196.8M | $44.7M |
| Gross Margin | — | 59.7% |
| Operating Margin | 6.3% | 19.9% |
| Net Margin | -40.9% | 13.2% |
| Revenue YoY | 9.5% | -2.7% |
| Net Profit YoY | -9940.0% | 19.3% |
| EPS (diluted) | $-1.23 | $0.95 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $339.0M | ||
| Q3 25 | $481.6M | $327.3M | ||
| Q2 25 | $464.7M | $321.4M | ||
| Q1 25 | $481.8M | $330.6M | ||
| Q4 24 | $465.2M | $348.5M | ||
| Q3 24 | $440.0M | $345.5M | ||
| Q2 24 | $423.3M | $336.2M | ||
| Q1 24 | $431.5M | — |
| Q4 25 | — | $44.7M | ||
| Q3 25 | $-196.8M | $38.7M | ||
| Q2 25 | $21.3M | $34.0M | ||
| Q1 25 | $14.9M | $58.0M | ||
| Q4 24 | $10.8M | $37.5M | ||
| Q3 24 | $2.0M | $33.8M | ||
| Q2 24 | $-1.8M | $38.4M | ||
| Q1 24 | $7.1M | — |
| Q4 25 | — | 59.7% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 59.8% | ||
| Q1 25 | — | 58.4% | ||
| Q4 24 | 47.0% | 55.5% | ||
| Q3 24 | 45.8% | 54.2% | ||
| Q2 24 | 44.1% | 52.0% | ||
| Q1 24 | 47.6% | — |
| Q4 25 | — | 19.9% | ||
| Q3 25 | 6.3% | 17.9% | ||
| Q2 25 | 9.1% | 16.8% | ||
| Q1 25 | 6.4% | 21.6% | ||
| Q4 24 | 6.1% | 16.9% | ||
| Q3 24 | 4.7% | 15.0% | ||
| Q2 24 | 3.3% | 11.8% | ||
| Q1 24 | 9.4% | — |
| Q4 25 | — | 13.2% | ||
| Q3 25 | -40.9% | 11.8% | ||
| Q2 25 | 4.6% | 10.6% | ||
| Q1 25 | 3.1% | 17.5% | ||
| Q4 24 | 2.3% | 10.8% | ||
| Q3 24 | 0.5% | 9.8% | ||
| Q2 24 | -0.4% | 11.4% | ||
| Q1 24 | 1.6% | — |
| Q4 25 | — | $0.95 | ||
| Q3 25 | $-1.23 | $0.81 | ||
| Q2 25 | $0.13 | $0.70 | ||
| Q1 25 | $0.09 | $1.17 | ||
| Q4 24 | $0.07 | $0.74 | ||
| Q3 24 | $0.01 | $0.66 | ||
| Q2 24 | $-0.01 | $0.74 | ||
| Q1 24 | $0.04 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $627.6M | $363.4M |
| Total DebtLower is stronger | $631.1M | $1.2B |
| Stockholders' EquityBook value | $2.7B | $911.5M |
| Total Assets | $8.7B | $2.5B |
| Debt / EquityLower = less leverage | 0.23× | 1.34× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $363.4M | ||
| Q3 25 | $627.6M | $296.4M | ||
| Q2 25 | $625.2M | $292.9M | ||
| Q1 25 | $557.3M | $306.8M | ||
| Q4 24 | $579.7M | $320.8M | ||
| Q3 24 | $494.1M | $299.3M | ||
| Q2 24 | $465.4M | $344.4M | ||
| Q1 24 | $392.5M | — |
| Q4 25 | — | $1.2B | ||
| Q3 25 | $631.1M | $1.2B | ||
| Q2 25 | $631.8M | $1.2B | ||
| Q1 25 | $632.4M | $1.2B | ||
| Q4 24 | $1.2B | — | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $1.2B | — | ||
| Q1 24 | $1.2B | — |
| Q4 25 | — | $911.5M | ||
| Q3 25 | $2.7B | $849.2M | ||
| Q2 25 | $2.7B | $882.3M | ||
| Q1 25 | $2.6B | $820.8M | ||
| Q4 24 | $2.5B | $906.9M | ||
| Q3 24 | $2.6B | $878.9M | ||
| Q2 24 | $2.5B | $905.4M | ||
| Q1 24 | $2.4B | — |
| Q4 25 | — | $2.5B | ||
| Q3 25 | $8.7B | $2.4B | ||
| Q2 25 | $8.5B | $2.5B | ||
| Q1 25 | $9.5B | $2.5B | ||
| Q4 24 | $9.1B | $2.5B | ||
| Q3 24 | $8.1B | $2.5B | ||
| Q2 24 | $9.0B | $2.5B | ||
| Q1 24 | $10.8B | — |
| Q4 25 | — | 1.34× | ||
| Q3 25 | 0.23× | 1.44× | ||
| Q2 25 | 0.23× | 1.39× | ||
| Q1 25 | 0.24× | 1.49× | ||
| Q4 24 | 0.47× | — | ||
| Q3 24 | 0.47× | — | ||
| Q2 24 | 0.49× | — | ||
| Q1 24 | 0.50× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $31.2M | $93.6M |
| Free Cash FlowOCF − Capex | — | $87.2M |
| FCF MarginFCF / Revenue | — | 25.7% |
| Capex IntensityCapex / Revenue | — | 1.9% |
| Cash ConversionOCF / Net Profit | — | 2.09× |
| TTM Free Cash FlowTrailing 4 quarters | — | $308.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $93.6M | ||
| Q3 25 | $31.2M | $111.3M | ||
| Q2 25 | $112.7M | $17.4M | ||
| Q1 25 | $49.6M | $116.6M | ||
| Q4 24 | $81.0M | $43.8M | ||
| Q3 24 | $91.8M | $48.8M | ||
| Q2 24 | $99.2M | $-27.4M | ||
| Q1 24 | $9.1M | — |
| Q4 25 | — | $87.2M | ||
| Q3 25 | — | $106.3M | ||
| Q2 25 | — | $13.6M | ||
| Q1 25 | — | $100.9M | ||
| Q4 24 | — | $35.2M | ||
| Q3 24 | — | $39.4M | ||
| Q2 24 | — | $-33.1M | ||
| Q1 24 | — | — |
| Q4 25 | — | 25.7% | ||
| Q3 25 | — | 32.5% | ||
| Q2 25 | — | 4.2% | ||
| Q1 25 | — | 30.5% | ||
| Q4 24 | — | 10.1% | ||
| Q3 24 | — | 11.4% | ||
| Q2 24 | — | -9.8% | ||
| Q1 24 | — | — |
| Q4 25 | — | 1.9% | ||
| Q3 25 | — | 1.5% | ||
| Q2 25 | — | 1.2% | ||
| Q1 25 | — | 4.7% | ||
| Q4 24 | — | 2.5% | ||
| Q3 24 | — | 2.7% | ||
| Q2 24 | — | 1.7% | ||
| Q1 24 | — | — |
| Q4 25 | — | 2.09× | ||
| Q3 25 | — | 2.88× | ||
| Q2 25 | 5.29× | 0.51× | ||
| Q1 25 | 3.33× | 2.01× | ||
| Q4 24 | 7.50× | 1.17× | ||
| Q3 24 | 45.90× | 1.44× | ||
| Q2 24 | — | -0.71× | ||
| Q1 24 | 1.28× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DAY
| Dayforce Recurring | $333.0M | 69% |
| Cloud And Bureau Professional Services And Other | $78.5M | 16% |
| Float | $42.2M | 9% |
| Powerpay Recurring | $19.7M | 4% |
| Other Recurring | $8.2M | 2% |
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
